Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to $32.6 million.

  • Relay Therapeutics' Total Current Liabilities fell 30.58% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year decrease of 30.58%. This contributed to the annual value of $50.7 million for FY2024, which is 67.59% up from last year.
  • Per Relay Therapeutics' latest filing, its Total Current Liabilities stood at $32.6 million for Q3 2025, which was up 0.25% from $32.5 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Total Current Liabilities peaked at $71.6 million during Q2 2023, and registered a low of $16.1 million during Q1 2021.
  • Moreover, its 3-year median value for Total Current Liabilities was $45.0 million (2024), whereas its average is $45.9 million.
  • In the last 5 years, Relay Therapeutics' Total Current Liabilities spiked by 161.95% in 2022 and then crashed by 52.49% in 2023.
  • Quarterly analysis of 5 years shows Relay Therapeutics' Total Current Liabilities stood at $24.3 million in 2021, then surged by 161.95% to $63.7 million in 2022, then slumped by 52.49% to $30.3 million in 2023, then skyrocketed by 67.59% to $50.7 million in 2024, then tumbled by 30.58% to $32.6 million in 2025.
  • Its Total Current Liabilities stands at $32.6 million for Q3 2025, versus $32.5 million for Q2 2025 and $37.1 million for Q1 2025.